Samsung Biologics has achieved a significant milestone in 2025, surpassing 3 trillion won ($2.2 billion) in cumulative contract orders just five months into the year, driven by a series of major deals with global pharmaceutical companies. This achievement represents over 60 percent of the company's total contract value for 2024, demonstrating accelerated growth in the contract manufacturing organization (CMO) sector.
Recent Contract Wins Drive Growth Momentum
The biotech arm of Samsung Group recently signed two new CMO deals totaling 440.5 billion won with pharmaceutical companies based in Europe and Asia. These contracts extend through December 2030 and December 2033, respectively, though client names and product details remain undisclosed due to non-disclosure agreements.
These latest agreements follow Samsung Biologics' largest-ever contract manufacturing deal, a 2.07 trillion won agreement signed in January with a European pharmaceutical firm, and a subsequent $513 million contract with a US-based pharmaceutical company worth 737.3 billion won that runs through the end of 2031.
So far in 2025, Samsung Biologics has signed four CMO deals across the US, Europe, and Asia, bringing the company's total cumulative contracts for the year to approximately 2.8 trillion won, accounting for more than 50 percent of last year's total deal value of 5.4 trillion won.
World's Largest Biomanufacturing Capacity
With the recent launch of its fifth plant in April, Samsung Biologics has expanded its total production capacity to 784,000 liters, establishing the world's largest biomanufacturing capacity. The new facility adds 180,000 liters of capacity to the company's operations in Songdo, Incheon.
"The launch of the fifth plant and our dedicated antibody-drug conjugate facility marks another milestone in expanding our capacity to cater to diverse client demands," said CEO John Rim, emphasizing the company's commitment to delivering long-term value for clients and shareholders through strategic investments in technology.
The company plans to further expand to eight production plants by 2032, targeting a combined production capacity of around 1.32 million liters to meet growing demand for biologics.
Strong Financial Performance and Quality Metrics
Samsung Biologics maintains exceptional operational performance, recording a 99 percent batch success rate last year and securing 356 manufacturing approvals from global regulators as of April 2025. The company now serves 17 of the world's top 20 pharmaceutical companies and has accumulated total orders of approximately $18.2 billion since its founding.
For the first quarter of 2025, Samsung Biologics' operating profit more than doubled to 486.7 billion won, compared to 221.3 billion won a year earlier, while sales rose 37.1 percent to 1.29 trillion won. Last year, the company posted record sales of 4.54 trillion won, up 23 percent from the previous year, while operating profit rose 19 percent to 1.32 trillion won.
"We sustained solid momentum in the first quarter, supported by the efficient operations across all our plants and continued partnerships with our clients," CEO Rim noted.
Strategic Expansion into Next-Generation Therapeutics
Samsung Biologics is strategically positioning itself in the next-generation cancer therapeutics market through its dedicated antibody-drug conjugate facility. The company has also expanded its global presence by recently opening a sales office in Japan, adding to its existing locations in New Jersey and Boston to strengthen relationships across key global markets.
To further expand its global presence, Samsung Biologics has actively participated in major industry events including the JPMorgan Healthcare Conference, DCAT Week 2025, and PEGS Boston. The company will next join the BIO International Convention in Boston this June to further strengthen its global partnerships and continue bolstering its contract pipeline throughout the year.
